The therapeutic use of dendritic cells transfected with tumour RNA

Bibliography

• SCANLON KJ: Anti-genes: siRNA, ribozymes and antisense. Curr. Pharm. BiotechnoL (2004) 5:415–420.
   PubMedGoogle Scholar
• ZHANG YC, TAYLOR MM, SAMSON WK, PHILLIPS MI: Antisense inhibition: oligonucleotides, ribozymes, and siRNAs. Methods Mol Med. (2005) 106:11–34.
   PubMedGoogle Scholar
• PHILLIPS MI: Antisense therapeutics: a promise waiting to be fulfilled. Methods Mol. Med. (2005) 106:3–10.
   PubMedGoogle Scholar
• GALARNEAU A, MIN KL, MANGOS MM, DAMHA MJ: Assay for evaluating ribonuclease H-mediated degradation of RNA-antisense oligonucleotide duplexes. Methods Mol. Biol. (2005) 288:65–80.
   PubMedGoogle Scholar
• CROOKE ST: Antisense strategies. Curr. Mol. Med. (2004) 4:465–487.
   PubMed Web of Science ®Google Scholar
• GOODCHILD J: Oligonucleotide therapeutics: 25 years agrowing. Curr. Opin. Mol. Ther. (2004) 6:120–128.
   PubMed Web of Science ®Google Scholar
• KASHANI-SABET M: Non-viral delivery of ribozymes for cancer gene therapy. Expert. Opin. Biol Ther. (2004) 4:1749–1755.
   PubMed Web of Science ®Google Scholar
• CORDELIER P, KULKOWSKY JW, KO C et al.: Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain HT antibody that targets CCR5. Gene Ther. (2004) 11:1627–1637.
   PubMed Web of Science ®Google Scholar
• SHIN KS, SULLENGER BA, LEE SW: Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. Mol. Ther. (2004) 10:365–372.
   PubMed Web of Science ®Google Scholar
• DIPAOLO JA, ALVAREZ-SALAS LM: Advances in the development of therapeutic nucleic acids against cervical cancer. Expert. Opin. Biol. Ther. (2004) 4:1251–1264.
   PubMed Web of Science ®Google Scholar
• PENNATI M, BINDA M, DE CESARE M et al.: Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis (2004) 25:1129–1136.
   Google Scholar
• PENNATI M, BINDA M, COLELLA G et al.: Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene (2004) 23:386–394.
   PubMed Web of Science ®Google Scholar
• SCHERER LJ, ROSSI JJ: Approaches forthe sequence-specific knockdown of mRNA. Nat. Biotechnol (2003) 21:1457–1465.
   PubMed Web of Science ®Google Scholar
• ELBASHIR SM, HARBORTH J, LENDECKEL W, YALCIN A, WEBER K, TUSCHL T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411:494-498. Report, that describes the revolutionary technique of siRNA to knock genes out in mammalian cells.
   Google Scholar
• MEISTER G, TUSCHL T: Mechanisms of gene silencing by double-stranded RNA. Nature (2004) 431:343-349. Review, that compares RNA silencing pathways in different organisms.
   Google Scholar
• TUSCHL T: Functional genomics: RNA sets the standard. Nature (2003) 421:220–221.
   PubMedGoogle Scholar
• ELBASHIR SM, HARBORTH J, WEBER K, TUSCHL T: Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods (2002) 26:199–213.
   PubMed Web of Science ®Google Scholar
• TUSCHL T: Expanding small RNA interference. Nat. BiotechnoL (2002) 20:446–448.
   PubMed Web of Science ®Google Scholar
• ELBASHIR SM, LENDECKEL W, TUSCHL T: RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. (2001) 15:188–200.
   PubMed Web of Science ®Google Scholar
• YING H, ZAKS TZ, WANG RF et al.: Cancer therapy using a self-replicating RNA vaccine. Nat. Med. (1999) 5:823–827.
   PubMed Web of Science ®Google Scholar
• XUE T, STAVROPOULOS E, YANG M et al.: RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection. Infect. Immun. (2004) 72:6324–6329.
   PubMed Web of Science ®Google Scholar
• HUNZIKER IP, HARKINS S, FEUER R, CORNELL CT, WHITTON JL: Generation and analysis of an RNA vaccine that protects against coxsackievirus B3 challenge. Virology (2004) 330:196–208.
   PubMed Web of Science ®Google Scholar
• BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392:245–252.
   PubMed Web of Science ®Google Scholar
• BANCHEREAU J, BRIERE F, CAUX C et al.: Immunobiology of dendritic cells. Ann. Rev Immunol (2000) 18:767-811. A thorough review of dendritic cell biology
   Google Scholar
• STEINMAN RM: The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol. (1991) 9:271–296.
   PubMed Web of Science ®Google Scholar
• SHORTMAN K, LIU YJ: Mouse and human dendritic cell subtypes. Nat. Rev. Immunol (2002) 2:151-161. Review, that compares the DC developmental pathways in humans and mice.
   Google Scholar
• FIGDOR CG, VAN KOOYK Y, ADEMA GJ: C-type lectin receptors on dendritic cells and Langerhans cells. Nat. Rev. Immunol. (2002) 2:77–84.
   PubMed Web of Science ®Google Scholar
• GUERMONPREZ P, VALLADEAU J, ZITVOGEL L, THERY C, AMIGORENA S: Antigen presentation and T cell stimulation by dendritic cells. Ann. Rev. Immunol. (2002) 20:621-667. This article reviews the unique role of DCs in the initiation of immune responses and the induction of tolerance.
   Google Scholar
• GRANUCCI F, ZANONI I, FEAU S, RICCIARDI-CASTAGNOLI P: Dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity. EMBO J. (2003) 22:2546–2551.
   PubMed Web of Science ®Google Scholar
• •This review discusses how dendritic cells control natural killer, T and B cell responses and the relevance of IL-2 in these processes.
   Google Scholar
• HACKSTEIN H, THOMSON AW: Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat. Rev. Immunol (2004) 4:24–34.
   PubMed Web of Science ®Google Scholar
• KUBO M, HANADA T, YOSHIMURA A:Suppressors of cytokine signaling and immunity. Nat. Immunol (2003) 4:1169–1176.
   PubMed Web of Science ®Google Scholar
• KOSCO-VILBOIS MH: Are follicular dendritic cells really good for nothing? Nat. Rev. Immunol (2003) 3:764–769.
   Google Scholar
• HABERMAN AM, SHLOMCHIK MJ: Reassessing the function of immune-complex retention by follicular dendritic cells. Nat. Rev. Immunol. (2003) 3:757–764.
   PubMed Web of Science ®Google Scholar
• BELZ GT, CARBONE FR, HEATH WR: Cross-presentation of antigens by dendritic cells. Crit Rev. Immunol (2002) 22:439–448.
   Google Scholar
• SHARP LL, JAMESON JM, WITHERDEN DA, KOMORI HK, HAVRAN WL: Dendritic epidermal T-cell activation. Crit Rev. Immunol. (2005) 25:1–18.
   PubMedGoogle Scholar
• HUANG AY, QI H, GERMAIN RN: Illuminating the landscape of in vivo immunity: insights from dynamic in situ imaging of secondary lymphoid tissues. Immunity. (2004) 21:331–339.
   Google Scholar
• SULLENGER BA, GILBOA E: Emerging clinical applications of RNA. Nature (2002) 418:252–258.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of innovative RNA-based therapeutic strategies.
   Google Scholar
• ELIAS M, VAN ZANTEN J, HOSPERS GA et al.: Closed system generation of dendritic cells from a single blood volume for clinical application in immunotherapy. j Clin. Apheresis. (2005) Epub ahead of print.
   Google Scholar
• TKACHENKO N, WOJAS K, TABARKIEWICZ J, ROLINSKI J: Generation of dendritic cells from human peripheral blood monocytes-comparison of different culture media. Folia Histochem. Cytobiol. (2005) 43:25–30.
   PubMedGoogle Scholar
• BERGER TG, STRASSER E, SMITH R et al.: Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells. J. Immunol Methods (2005) 298:61–72.
   PubMed Web of Science ®Google Scholar
• TAKEDA A, KOMITA H, TAKAGI Y et al.: Repeated administration of cytokines improve the ex vivo generation of human dendritic cells. J. Exp. Clin. Cancer Res. (2004) 23:617–623.
   PubMedGoogle Scholar
• CELLUZZI CM, WELBON C: Dendritic cell culture: a simple closed culture system using Ficoll, monocytes, and a table-top centrifuge. J. Hematother. Stem Cell Res. (2003) 12:575–585.
   PubMedGoogle Scholar
• BABATZ J, ROLLIG C, OELSCHLAGEL U et al.: Large-scale immunomagnetic selection of CD14* monocytes to generate dendritic cells for cancer immunotherapy: a Phase I study. J. Hematother. Stem Cell Res. (2003) 12:515–523.
   PubMedGoogle Scholar
• FELZMANN T, WITT V, WIMMER D et al.: Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection. Cytotherapy. (2003) 5:391–398.
   PubMed Web of Science ®Google Scholar
• LAPENTA C, SANTINI SM, LOGOZZI M et al.: Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-a. J. Exp. Med. (2003) 198:361–367.
   PubMed Web of Science ®Google Scholar
• PULLARKAT V, LAU R, LEE SM, BENDER JG, WEBER JS: Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells. J. Immunol. Methods (2002) 267:173–183.
   PubMed Web of Science ®Google Scholar
• REINHARD G, MARTEN A, KISKE SM, FEIL F, BIEBER T, SCHMIDT-WOLF IG: Generation of dendritic cell-based vaccines for cancer therapy. Br. J. Cancer (2002) 86:1529–1533.
   PubMed Web of Science ®Google Scholar
• MARROQUIN CE, WESTWOOD JA, LAPOINTE R et al.: Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. J. Immunother. (2002) 25:278–288.
   PubMedGoogle Scholar
• POSPISILOVA D, BOROVICKOVA J, POLOUCKOVA A et al.: Generation of functional dendritic cells for potential use in the treatment of acute lymphoblastic leukemia. Cancer Immunol Immunother. (2002) 51:72–78.
   PubMed Web of Science ®Google Scholar
• BAI L, FEUERER M, BECKHOVE P, UMANSKY V, SCHIRRMACHER V: Generation of dendritic cells from human bone marrow mononuclear cells: advantages for clinical application in comparison to peripheral blood monocyte derived cells. Int. J. Oncol (2002) 20:247–253.
   PubMed Web of Science ®Google Scholar
• DIECKMANN D, SCHULTZ ES, RING B et al.: Optimizing the exogenous antigen loading of monocyte-derived dendritic cells. Int. Immunol (2005) 17:621–635.
   PubMedGoogle Scholar
• MORELLI AE, LARREGINA AT, SHUFESKY WJ et al.: Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood (2004) 104:3257–3266.
   PubMed Web of Science ®Google Scholar
• SHIMIZU K, KURIYAMA H, KJAERGAARD J, LEE W, TANAKA H, SHU S: Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J. Immunother. (2004) 27:265–272.
   PubMed Web of Science ®Google Scholar
• ACKERMAN AL, CRESS WELL P: Cellular mechanisms governing cross-presentation of exogenous antigens. Nat. Immunol (2004) 5:678–684.
   PubMed Web of Science ®Google Scholar
• ••This article discusses the potentialmechanisms involved in loading exogenous antigens onto MHC class I molecules.
   Google Scholar
• VARI F, HART DN: Loading DCs with Ag. Cytotherapy. (2004) 6:111–121.
   PubMed Web of Science ®Google Scholar
• TANAKAY, DOWDY SF, LINEHAN DC, EBERLEIN TJ, GOEDEGEBUURE PS: Induction of antigen-specific CTL by recombinant HIV trans-activating fusion protein-pulsed human monocyte-derived dendritic cells. J. Immunol (2003) 170:1291–1298.
   PubMedGoogle Scholar
• HOWARTH M, ELLIOTT T: The processing of antigens delivered as DNA vaccines. Immunol Rev. (2004) 199:27–39.
   PubMed Web of Science ®Google Scholar
• SCHNURR M, GALAMBOS P, SCHOLZ C et al.: Tumor cell lysate-pulsed human dendritic cells induce a T cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res. (2001) 61:6445–6450.
   PubMed Web of Science ®Google Scholar
• VAN TENDELOO VF, PONSAERTS P, LARDON F et al.: Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood (2001) 98:49–56.
   PubMed Web of Science ®Google Scholar
• •Key paper that describes RNA electroporation as a powerful technique to charge human dendritic cells with tumour antigens.
   Google Scholar
• GRONEBACH F, MOLLER MR, NENCIONI A. BROSSART P: Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther. (2003) 10:367–374.
   Google Scholar
• GRONEBACH F, MOLLER MR, BROSSART P: RNA transfection of dendritic cells. Methods Mol Med. (2005) 109:47–54.
   PubMedGoogle Scholar
• GRONEBACH F, KAYSER K et al: Co-transfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the Induction of tumor antigen specific cytotoxic T lymphocytes. Cancer Gene Ther. (2005).
   Google Scholar
• GRONEBACH F, MOLLER MR, BROSSART P: New developments in dendritic cell-based vaccinations: RNA translated into clinics. Cancer Immunol Immunother. (2005) 54:517–525.
   PubMedGoogle Scholar
• WEISSMAN D, NI H, SCALES D et al: HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J. Immunol (2000) 165:4710–4717.
   PubMedGoogle Scholar
• STROBEL I, BERCHTOLD S, GOTZE A, SCHULZE U, SCHULER G, STEINKASSERER A: Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther. (2000) 7:2028–2035.
   PubMed Web of Science ®Google Scholar
• OSMAN Y, NARITA M, AYRES F et aL:Generation of Ag-specific cytotoxic T lymphocytes by DC transfected with in vitro transcribed influenza virus matrix protein (M1) mRNA. Cytotherapy (2003) 5:161–168.
   PubMed Web of Science ®Google Scholar
• NAIR S, BOCZKOWSKI D: RNA -transfected dendritic cells. Expert. Rev. Vaccines. (2002) 1:507–513.
   PubMedGoogle Scholar
• BOZZA S, MONTAGNOLI C, GAZIANO R et al.: Dendritic cell-based vaccination against opportunistic fungi. Vaccine (2004) 22:857–864.
   PubMed Web of Science ®Google Scholar
• BOCZKOWSKI D, NAIR SK, SNYDER D, GILBOA E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. (1996) 184:465–472.
   PubMed Web of Science ®Google Scholar
• ••First report that shows that DC pulsed with RNA are highly potent APC, capable of stimulating primary CTL responses.
   Google Scholar
• NAIR SK, BOCZKOWSKI D, MORSE M, CUMMING RI, LYERLY HK, GILBOA E: Induction of primary carcinoembryonic antigen (CFA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol (1998) 16:364–369.
   PubMed Web of Science ®Google Scholar
• SAEBOE-LARSSEN S, FOSSBERG E, GAUDERNACK G: mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). j Immunol Methods (2002) 259: 191–203.
   PubMed Web of Science ®Google Scholar
• DORFEL D, APPEL S, GRONEBACH F et al.: Processing and presentation of HLA class land II epitopes by dendritic cells after transfection with in vitro transcribed MUC1 RNA. Blood (2004).
   Google Scholar
• MOLLER MR, GRONEBACH F, NENCIONI A, BROSSART P: Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J. Immunol (2003) 170:5892–5896.
   PubMedGoogle Scholar
• MOLLER MR, TSAKOU G, GRONEBACH F, SCHMIDT SM, BROSSART P: Induction of chronic lymphocytic leukemia (CLL)-specific CD4-and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood (2004) 103: 1763-1769.
   Google Scholar
• NENCIONI A, MOLLER MR, GRONEBACH F et al: Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer. Cancer Gene Ther. (2003) 10:209–214.
   PubMed Web of Science ®Google Scholar
• MILAZZO C, REICHARDT VL, MOLLER MR, GRONEBACH F, BROSSART P: Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood (2003) 101:977–982.
   PubMed Web of Science ®Google Scholar
• HEISER A, MAURICE MA, YANCEY DR, COLEMAN DM, DAHM P, VIEWEG J: Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res. (2001) 61:3388–3393.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI T, YAIVIANAKA R, HOMMA J et al.: Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8* cytotoxic T cells in patients with malignant glioma. Cancer Immunol Immunother. (2003) 52:632–637.
   PubMed Web of Science ®Google Scholar
• HOERR I, OBST R, RAMMENSEE HG, JUNG G: In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. Immunol (2000) 30:1–7.
   PubMed Web of Science ®Google Scholar
• ••Report that demonstrates that direct injection of RNA can elicit a specific immune response in mice.
   Google Scholar
• CARRALOT JP, PROBST J, HOERR I et al.: Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell Md. Life Sci. (2004) 61:2418–2424.
   PubMed Web of Science ®Google Scholar
• •Analysis of globin-stabilised mRNA-based vaccination in mice.
   Google Scholar
• GRANSTEIN RD, DING W, OZAWA H: Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J. Invest. DermatoL (2000) 114:632–636.
   PubMed Web of Science ®Google Scholar
• ISHII KJ, AKIRA S: Innate immune recognition of nucleic acids: Beyond toll-like receptors. Int. J. Cancer (2005) 117:517–523.
   PubMed Web of Science ®Google Scholar
• HORNUNG V GUENTHNER-BILLER M, BOURQUIN C et al: Sequence-specific potent induction of IFN-a by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. (2005) 11:263–270.
   PubMed Web of Science ®Google Scholar
• ••This paper describes immunostimulatoryRNA (isRNA) as an additional biological activity of siRNA.
   Google Scholar
• HEISER A, COLEMAN D, DANNULL J et al: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest (2002) 109:409–417.
   PubMed Web of Science ®Google Scholar
• •First Phase I trial using autologous dendritic cells transfected with mRNA.
   Google Scholar
• SU Z, DANNULL J, YANG BK et al: Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8* and CD4* T cell responses in patients with metastatic prostate cancer. J. Immunol (2005) 174:3798–3807.
   PubMed Web of Science ®Google Scholar
• •This paper reports on a clinical trial in which hTERT mRNA-transfected dendritic cells were administered to patients with metastatic prostate cancer.
   Google Scholar
• MORSE MA, NAIR SK, MOSCA PJ et al.:Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest. (2003) 21:341–349.
   PubMed Web of Science ®Google Scholar
• NAIR SK, MORSE M, BOCZKOWSKI D et al.: Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg. (2002) 235:540–549.
   PubMed Web of Science ®Google Scholar
• SU Z, DANNULL J, HEISER A et al.: Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. (2003) 63:2127–2133.
   PubMed Web of Science ®Google Scholar
• ••This article reports on a Phase I trial thatutilises autologous dendritic cells transfected with total tumour RNA.
   Google Scholar
• SCHEEL B, BRAEDEL S, PROBST J et al.: Immunostimulating capacities of stabilized RNA molecules. Eur. J. Immunol (2004) 34:537–547.
   PubMed Web of Science ®Google Scholar
• SCHEEL B, TEUFEL R, PROBST J et al.: Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur. J. Immunol (2005) 35:1557–1566.
   PubMed Web of Science ®Google Scholar
• •The studies presented here explain the capacity of protamine-RNA to act as a vaccine.
   Google Scholar
• SU Z, VIEWEG J, WEIZER AZ et al.: Enhanced induction of telomerase-specific CD4* T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res. (2002) 62:5041–5048.
   PubMed Web of Science ®Google Scholar
• •This report describes the usage of genetic engineered RNA for the concomitant induction of specific CDS* and CD4* T-cell responses.
   Google Scholar
• NAIR S, BOCZKOWSKI D, MOELLER B, DEWHIRST M, VIEWEG J, GILBOA E: Synergy between tumor immunotherapy and antiangiogenic therapy. Blood (2003) 102:964–971.
   PubMed Web of Science ®Google Scholar
• •This study shows that anti-angiogenesis and anti-tumour treatment can be achieved by concomitant administration of two specific RNAs.
   Google Scholar
• DANNULL J, NAIR S, SU Z et al.: Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood (2005) 105:3206–3213.
   PubMed Web of Science ®Google Scholar
• •First report demonstrating that DC function can be significantly improved by transfection with RNA encoding a co-stimulatory molecule.
   Google Scholar